title: [The effect of sibutramine on weight loss in obese adolescents].
abstract: OBJECTIVE
  To evaluate the effect of sibutramine on weight loss in obese adolescents.
  
  
  METHODS
  A double-blind controlled study lasting 13 months. The study included 73 obese adolescents of both sexes aged between 10 and 18 years. Laboratory tests and imaging studies were performed before, during wash-out, and at the end of 13 months.
  
  
  RESULTS
  The percentage of patients who lost 10% of their initial weight in the placebo group was 46%, and in the sibutramine group was 75%. When placebo was used, average weight rose by 1.61 kg, and BMI decreased by 0.24 kg/m(2) whereas with the use of sibutramine, weight decreased by 4.47 kg, and average BMI decreased, 2.38 kg/m(2), with p < 0.001.
  
  
  CONCLUSIONS
  Sibutramine induced significantly more weight loss in obese adolescents compared with placebo, without significant side effects. The weight loss curve was different depending on the moment sibutramine was introduced. This finding indicates that the best time to start sibutramine is when adhesion begins to fail.
authors.affiliation: Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
authors.forename: Ruth Rocha
authors.initials: RR
authors.lastname: Franco
authors.affiliation: Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
authors.forename: Louise
authors.initials: L
authors.lastname: Cominato
authors.affiliation: Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.
authors.forename: Durval
authors.initials: D
authors.lastname: Damiani
mesh_terms: D000293:Adolescent; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D002648:Child; D002784:Cholesterol / Q000097:blood; D018592:Cross-Over Studies; D003503:Cyclobutanes / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D061214:Patient Safety; D063766:Pediatric Obesity / Q000097:blood / Q000188:drug therapy*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D001067:Appetite Depressants; D001786:Blood Glucose; D003503:Cyclobutanes; D007328:Insulin; D020738:Leptin; D014280:Triglycerides; D002784:Cholesterol; C058254:sibutramine